Why Digital Therapeutics Are Becoming a Medical-Liability Risk Reinsurers Must Price

Digital therapeutics, software applications prescribed to prevent, manage, or treat medical conditions, are moving from pilot programs to formulary listings, and each prescription writes a product-liability exposure that the reinsurance market has not fully priced. When an app that manages type-2 diabetes recommends an insulin dose, or a cognitive behavioral therapy app fails a patient in crisis, the resulting claim involves software-product liability, clinical evidence standards, and questions about whether the prescribing clinician or the software manufacturer bears responsibility for the outcome. The clinical evidence that regulators require for market clearance is also becoming the standard by which liability is judged, and reinsurers need to understand both.

Why does software-as-medicine change the product-liability framework?

Software-as-medicine changes the product-liability framework because digital therapeutics are continuously updated, algorithmically driven, patient-operated products that sit in the same liability category as drugs and devices but behave like neither. A pharmaceutical product has a fixed chemical composition; a digital therapeutic has a software version that changes every few months. A medical device has defined mechanical specifications; a digital therapeutic has algorithms whose behavior may vary across patient populations in ways the clinical trials did not fully characterize. The product-liability reinsurance framework built for stable, physical products does not map cleanly onto continuously evolving, algorithmically adaptive software.

The emerging risk dimension is that digital therapeutics are being prescribed at scale before the liability framework has matured. Regulators have established clearance pathways, payers have established reimbursement codes, and clinicians are writing prescriptions. The claims are beginning to accumulate, and the reinsurance market is pricing them with tools designed for a different product class. The clinical evidence that supported market clearance is the key to closing the gap, because it defines the standard against which the product's safety will be judged.

What goes wrong when digital therapeutics fail patients?

Digital therapeutics fail patients through five distinct pathways: algorithmic errors that produce clinically harmful recommendations, engagement failures that cause patient deterioration through non-use, software-update errors that introduce new failure modes, data-integrity failures that corrupt clinical information, and interoperability errors that disrupt the patient's broader care ecosystem.

Each pathway generates a different liability profile, and the clinical evidence the manufacturer produced for regulatory clearance is the benchmark against which the failure is measured. Reinsurers need to understand both the failure modes and the evidence context to price the exposure.

1. How do algorithmic errors generate product-liability claims?

Algorithmic errors generate product-liability claims when the therapeutic's software makes a recommendation that causes clinical harm: an insulin-dosing algorithm that recommends an excessive dose, a mental-health chatbot that fails to recognize suicidal ideation, or a substance-use-disorder therapeutic that reinforces rather than reduces addictive behavior. The error is in the code, the training data, or the clinical logic, and the harm is directly traceable to the product.

This is the clearest product-liability scenario. The loss development analysis that tracks algorithmic-error claims can identify whether errors cluster around specific therapeutic categories, specific patient subpopulations, or specific software versions. For reinsurers, the aggregation risk is that an algorithmic error embedded in a therapeutic prescribed to fifty thousand patients can produce fifty thousand liability events from a single root cause.

2. What happens when patient engagement fails?

When patient engagement fails, the patient stops using the therapeutic, and their underlying condition worsens. The question for liability purposes is whether the therapeutic's design contributed to the disengagement. Was the user interface too complex for the target population? Did the therapeutic fail to adapt its approach when the patient showed signs of disengagement? Did it provide adequate escalation when a patient with a high-risk condition stopped logging in?

The clinical evidence is central here. If the manufacturer's pivotal trial showed high engagement in a controlled setting but real-world engagement is dramatically lower, the question is whether the product was designed for the real-world conditions in which it is prescribed. A risk assessment framework that evaluates real-world engagement data against clinical-trial engagement data can identify products where the gap creates liability exposure.

3. How do software updates create new liability exposure?

Software updates create new liability exposure because each update changes the product. A therapeutic cleared by regulators based on clinical evidence from version 2.0 may, after several updates to version 2.7, be a materially different product whose safety profile has not been validated in the same way. If a patient is harmed by a feature introduced in version 2.4, the question is whether the manufacturer maintained the product's safety through the update cycle.

This is the continuous-change liability problem. Each software update is a new product-liability cohort, and the reinsurer needs to be able to isolate claims by version to price each cohort's risk. A treaty analysis that tracks claims by software version can identify whether update-related claims are increasing, stable, or declining, and adjust pricing accordingly.

4. Why do data-integrity failures create liability?

Data-integrity failures create liability when the therapeutic corrupts, loses, or misreports clinical data that the patient or clinician relies on. A blood-glucose log that drops readings, a symptom tracker that records the wrong severity, or a medication-reminder system that sends reminders for the wrong drug or the wrong time all create clinical risk through data failure.

These claims sit at the boundary of product liability and professional liability. If the clinician made a treatment decision based on corrupted data from the therapeutic, the manufacturer may argue the clinician should have verified the data independently. The data quality checker that monitors therapeutic data integrity can establish whether data failures were systematic, pointing to a product defect, or isolated, pointing to user or environmental factors.

5. How do interoperability errors affect the patient's care ecosystem?

Interoperability errors affect the patient's care ecosystem when the digital therapeutic exchanges data with electronic health records, pharmacy systems, remote monitoring devices, or other clinical software, and data is lost, corrupted, or delayed in the exchange. The therapeutic may function correctly in isolation but cause harm through incorrect integration.

This is a multi-vendor liability problem. The multi-treaty exposure tracker that maps the therapeutic's interoperability interfaces can identify where integration failures create liability and which vendors carry the exposure for which interfaces. For reinsurers, the concern is that a single interface defect can affect every patient whose data crosses that interface, creating an aggregation exposure that spans the therapeutic's entire installed base.

Price digital therapeutic liability with the clinical evidence the regulators already require

Talk to Our Specialists

Visit Insurnest to learn how we help reinsurers analyze digital therapeutic clinical evidence, track software-version risk, and price the software-as-medicine exposure with evidence-grade precision.

What do emerging-tech analysts actually expect from digital therapeutic submissions?

Emerging-tech analysts expect clinical-evidence packages with study design and population data, software-version deployment maps, patient-population data by indication, real-world engagement analytics, adverse-event registries with version and patient-segment correlation, interoperability-interface inventories, and continuous-update governance documentation.

Consider Maya, an emerging-tech analyst at a reinsurer whose portfolio includes several digital therapeutic manufacturers. Her role is to assess risks that do not fit neatly into existing underwriting categories, and digital therapeutics are her most complex assignment. The manufacturers she evaluates produce apps for diabetes management, mental health, substance-use disorder, chronic pain, and insomnia. Each product has FDA clearance or CE marking, clinical evidence from randomized trials, and a growing base of prescribed patients, but the submissions she receives describe the business and the regulatory status without describing the risk.

Maya's concern is that digital therapeutic liability is being underwritten on the regulatory clearance alone, as if clearance were a guarantee of safety rather than a point-in-time assessment of a product that changes continuously. She knows that the clinical evidence that supported clearance is also the evidence that will be used in litigation, and she needs to evaluate it as an underwriter, not just accept the clearance as a proxy.

What Maya actually needs from her submissions is the evidence-depth package that distinguishes a well-understood digital therapeutic from one that is cleared but not fully characterized.

• "Provide the full clinical-evidence package, not just the clearance letter." The study design, population, endpoints, and statistical analysis determine whether the evidence supports the product's safety claims, and the reinsurer needs to evaluate that evidence directly.
• "Map the installed base by software version, indication, and patient population." A therapeutic cleared for type-2 diabetes in adults that is being used off-label for prediabetes in adolescents carries exposure outside the clinical-evidence envelope, and the treaty needs to price that exposure.
• "Track real-world engagement and adherence data against the clinical-trial benchmarks." If eighty percent of patients in the trial completed the therapeutic but only forty percent do in the real world, the real-world safety profile differs from the trial safety profile in ways the reinsurer needs to understand.
• "Maintain an adverse-event registry that tags each event to the software version, patient demographics, and clinical indication at the time of the event." A safety signal that appears in one software version or one patient subpopulation is actionable underwriting data that the aggregate claims history obscures.
• "Describe the software-update governance process: what testing is performed before each release, how safety is validated post-release, and how adverse-event monitoring continues after each update." Continuous change requires continuous safety surveillance, and the reinsurer needs to evaluate the manufacturer's process.
• "Disclose the algorithmic methodology and training-data characteristics for any AI or machine-learning components." An algorithm trained on a population that does not match the prescribed population may produce systematically different recommendations, and that mismatch is a product-liability exposure.
• "Inventory all interoperability interfaces and data exchanges, with failure-mode analyses for each." A therapeutic that sends insulin-dosing recommendations to a pharmacy system has a different interface-risk profile from one that provides standalone cognitive exercises, and the submission should distinguish them.
• "Report on patient-population drift: is the real-world prescribed population matching the clinical-trial population, or is it expanding into unstudied groups?" When the prescribed population diverges from the studied population, the clinical evidence no longer describes the product's safety in use, and the liability exposure changes.
• "Track clinician prescribing patterns and off-label use." If the therapeutic is being prescribed for indications, populations, or in combination with other therapies that were not studied, the manufacturer may face liability for failing to manage off-label use despite knowing it is occurring.
• "Model the worst-case algorithmic failure: a dosing error affecting all patients on a specific software version across all indications." This is the aggregation scenario the treaty needs to survive, and the submission should model it explicitly.

Maya's analysis framework is evidence-based in the clinical sense and the actuarial sense. The data to support that framework exists in the regulatory submissions, the software-development records, and the real-world evidence the manufacturers are already collecting. What is missing is the translation of that data into the underwriting and reinsurance pricing pipeline.

How can digital therapeutic product liability be priced with clinical evidence?

Digital therapeutic product liability can be priced with clinical evidence by evaluating the clinical-trial data against real-world deployment data, tracking software-version risk, modeling patient-engagement failure scenarios, assessing algorithmic-bias exposure, mapping interoperability-failure aggregation, and building a continuous-surveillance framework that updates pricing with each software release and each new evidence artifact.

The capabilities below describe how clinical evidence becomes the foundation for reinsurance pricing of digital therapeutics.

1. How does clinical-evidence evaluation inform treaty pricing?

Clinical-evidence evaluation informs treaty pricing by assessing the strength, relevance, and generalizability of the evidence supporting each therapeutic. A product backed by multiple large randomized trials in populations matching the prescribed population earns lower pricing than a product backed by a single small trial in a narrow population, even if both products have regulatory clearance.

This is underwriting intelligence applied to clinical evidence. The reinsurer evaluates the evidence not as a regulator assessing market access but as a risk-bearer assessing the likelihood that the product will generate claims that the evidence did not predict. The stronger the evidence, the narrower the gap between the known safety profile and the real-world safety experience, and the lower the uncertainty load in the treaty price.

2. What does real-world-versus-trial comparison deliver?

Real-world-versus-trial comparison delivers the ability to identify products whose real-world performance diverges from their clinical-trial performance. A therapeutic whose real-world engagement is half the trial engagement rate, or whose real-world adverse-event rate is three times the trial rate, carries exposure the clinical evidence alone does not describe.

This requires the manufacturer to collect and share real-world data, and it requires the reinsurer to have the analytics to compare it to the trial data. A loss development anomaly detector that ingests both datasets can flag products where the real-world experience is diverging from the expected experience, enabling pricing adjustments at renewal rather than after claims accumulate.

3. How should software-version risk be managed in a continuous-update environment?

Software-version risk should be managed by treating each major software release as a new product requiring its own risk assessment. A therapeutic on version 3.0 may have a different safety profile from the same therapeutic on version 2.0, and the treaty should be priced to reflect the version distribution in the installed base.

This requires version-level exposure tracking. The reinsurer needs to know how many patients are on each version, what changed in each version, and what the adverse-event rate is for each version. The version with the most patients and the least clinical evidence creates the largest exposure window, and that window is what the treaty needs to price.

4. Why does algorithmic-bias assessment matter for liability pricing?

Algorithmic-bias assessment matters because a therapeutic whose algorithm performs differently across demographic groups generates liability exposure that is concentrated in the populations where it performs poorly. If the algorithm was trained predominantly on data from one demographic group and performs less accurately on others, the resulting errors are a product-defect pattern that the manufacturer should have anticipated.

This is pricing unknown risk made measurable through algorithmic fairness analysis. The reinsurer who evaluates the algorithm's performance across demographic subgroups can identify the populations where the therapeutic carries elevated liability exposure and price that exposure, or exclude it, rather than discovering it through claims.

5. How can interoperability-failure scenarios be modeled?

Interoperability-failure scenarios can be modeled by mapping each digital therapeutic's data-exchange interfaces, identifying the clinical consequences of data failures at each interface, and estimating the worst-case patient impact of an interface-wide failure. A therapeutic that sends medication-dosing recommendations to an EHR or pharmacy system carries higher interface-failure severity than one that sends step-count data to a wellness dashboard.

This is aggregation modeling applied to software interfaces. The reinsurer needs to understand which interfaces are patient-safety-critical and model the failure of each one as a scenario that can breach the treaty. The interface map is the underwriting data that enables that modeling.

6. What does continuous safety surveillance deliver for treaty renewal?

Continuous safety surveillance delivers the ability to update the treaty price at each renewal based on the real-world safety data accumulated since the last renewal. Each software release, each new clinical study, each real-world evidence report, and each adverse-event signal becomes an input to the pricing model, and the treaty price reflects the current risk rather than the risk at the time of the original regulatory clearance.

This is AI-driven underwriting applied to post-market surveillance. The framework treats the digital therapeutic as a continuously characterized risk rather than a point-in-time-approved product, and the pricing converges on the true risk as the evidence accumulates. For a product class where the risk profile is still being written, that continuous-update capability is the difference between pricing the known and guessing at the unknown.

Build evidence-driven digital therapeutic pricing with Insurnest's clinical-analytics technology

Talk to Our Specialists

Visit Insurnest to see how we help reinsurers and digital-health insurers evaluate clinical evidence, track software-version risk, and price the software-as-medicine exposure that is reshaping the product-liability landscape.

What does an evidence-informed digital therapeutic submission look like?

An evidence-informed digital therapeutic submission provides clinical-evidence packages evaluated for strength and generalizability, software-version deployment maps, real-world-versus-trial comparison data, patient-population drift analysis, algorithmic-bias assessments, interoperability-failure models, and continuous-surveillance reports that update the risk profile at each renewal. The reinsurer can price each therapeutic based on its evidence base, version distribution, and real-world safety experience rather than on its regulatory category alone.

Return to Maya's analysis desk, but with a submission built on the clinical evidence the manufacturer already possesses. The evidence package includes the pivotal trials, the post-market studies, and the real-world evidence reports, with a structured comparison showing where real-world engagement, adherence, and adverse-event rates diverge from the trial benchmarks. The software-version map shows the installed-base distribution across versions, and the adverse-event registry tags each event to its software version, patient demographics, and clinical indication.

The algorithmic-bias analysis, conducted by an independent evaluator, shows that the therapeutic's cognitive behavioral therapy module performs equivalently across demographic groups, but its medication-reminder module shows lower accuracy for patients over seventy, a finding the manufacturer is addressing in the next software release. The interoperability map identifies the pharmacy-system interface as the highest-risk data exchange, and a failure scenario models the clinical impact of a pharmacy-interface outage affecting the entire installed base. The treaty limit accommodates the scenario at the ninety-ninth percentile, and the submission documents the calculation.

Maya's pricing model now operates on evidence segments: each therapeutic is priced based on its evidence strength, its real-world safety experience, its version risk, and its interface-risk profile. The renewal conversation is about the manufacturer's evidence-generation pipeline and its software-release roadmap, not about whether the therapeutic is a product-liability exposure at all. The submission has done the evidence work, so the negotiation can do the commercial work.

The digital therapeutic market is scaling rapidly, and the reinsurance market that prices it with clinical-evidence rigor will earn the returns that the risk-adjusted pricing justifies. The manufacturers who invest in evidence generation and share that evidence with their reinsurers will earn the terms that evidence-poor competitors cannot access. The enterprise risk strategy for digital therapeutic manufacturers now includes reinsurance-communication as a core component, because the evidence that supports market access is the same evidence that supports reinsurance pricing, and the firms that connect the two will lead the market.

Deliver the evidence-informed digital therapeutic submission that earns the terms your product deserves

Talk to Our Specialists

Visit Insurnest to learn how we help digital therapeutic manufacturers and their reinsurers build evidence-driven submissions that translate clinical data into reinsurance pricing with the precision this product class demands.

Conclusion

Digital therapeutics are creating a product-liability category that sits at the intersection of pharmaceuticals, medical devices, and software, and the reinsurance market needs a pricing framework that reflects all three. The clinical evidence that regulators require for market clearance is the natural foundation for that framework, because it defines the safety standard against which product-liability claims will be judged. The manufacturers who generate robust evidence and share it with their reinsurers will earn the pricing that evidence-supported products deserve; those who treat regulatory clearance as the end of the safety conversation will face uncertainty loads that reflect the reinsurer's inability to verify what the clearance represents.

For emerging-tech analysts, digital-health underwriters, and their reinsurers, the practical response is to build clinical-evidence evaluation into the underwriting pipeline. Evidence-strength assessment, real-world-versus-trial comparison, software-version risk tracking, algorithmic-bias analysis, interoperability-failure modeling, and continuous safety surveillance are not academic additions to the submission. They are the data infrastructure that converts a digital therapeutic from a novel exposure into a priced and managed one.

The digital therapeutic market will continue to expand across disease categories and patient populations, and the claims will continue to develop. The reinsurers who price them with clinical-evidence rigor will write the book profitably as it scales. Those who price them on regulatory status alone will discover the gap between clearance and safety through claims that the evidence, properly evaluated, would have anticipated. The clinical data already exists; the reinsurance industry's task is to read it with an underwriter's eye.

Frequently asked questions

What makes digital therapeutics a product-liability exposure?

Digital therapeutics are software products prescribed to treat medical conditions. When they fail, cause harm, or malfunction affecting patient health, the manufacturer faces product-liability claims under the same theories as pharmaceutical and device manufacturers.

How do clinical evidence standards affect digital therapeutic liability?

Regulatory clearance requires evidence of safety and efficacy. When a digital therapeutic causes harm, the evidence strength determines whether the product was defectively designed, inadequately tested, or reasonably safe given the science.

What are the main failure modes in prescription digital therapeutics?

Main failure modes include algorithmic errors recommending harmful actions, engagement failures where patients stop using the therapeutic, data-privacy breaches exposing health information, and interoperability errors with other medical software used in patient care.

How should reinsurers approach digital therapeutic aggregation risk?

A single software defect can affect every patient using that version across multiple disease indications. Reinsurers should require version-level deployment data, adverse-event tracking by version, and patient-population data to model worst-case aggregated exposure.

How does digital therapeutic liability differ from conventional medical device liability?

Digital therapeutics are updated continuously, not manufactured in fixed batches. Today's product may differ from the cleared one, and each update introduces new failure modes, challenging traditional liability frameworks built on stable product definitions.

What role does patient engagement data play in liability analysis?

Patient engagement data shows whether the therapeutic was used as prescribed. If a patient deteriorates after discontinuing, the manufacturer may argue it was not causal, but if design contributed to disengagement, liability may still attach.

What data should cedents provide for digital therapeutic submissions?

Cedents should provide software-version deployment maps, patient-population data by indication, clinical-evidence packages with study methodologies, adverse-event registries with version correlation, engagement-analytics data, and interoperability inventories listing all connected clinical systems.

How does digital therapeutic liability interact with clinician malpractice coverage?

When a prescribed digital therapeutic harms a patient, both manufacturer and prescriber may face liability for inappropriate prescribing or product defects, creating clash exposure across coverage lines.

About the author

Hitul Mistry is the Founder of Insurnest, an InsurTech company that engineers end-to-end technology exclusively for the insurance industry serving carriers, TPAs, MGAs, brokers, and reinsurers across India, the UAE, and the US. With more than a decade of insurance domain experience, he has built systems spanning underwriting automation, AI-powered underwriting intelligence, claims management, rating and quoting, broking and agency platforms, and reinsurance automation across Health/GMC, Group Life, Motor, P&C, and Reinsurance. Insurnest doesn't adapt generic software to insurance; it builds from the workflow up.

Connect with Hitul on LinkedIn.